JP2017537925A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537925A5 JP2017537925A5 JP2017529746A JP2017529746A JP2017537925A5 JP 2017537925 A5 JP2017537925 A5 JP 2017537925A5 JP 2017529746 A JP2017529746 A JP 2017529746A JP 2017529746 A JP2017529746 A JP 2017529746A JP 2017537925 A5 JP2017537925 A5 JP 2017537925A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims description 326
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 260
- 238000012986 modification Methods 0.000 claims description 225
- 230000004048 modification Effects 0.000 claims description 210
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 133
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 80
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 77
- 229920001184 polypeptide Polymers 0.000 claims description 76
- -1 amino Chemical group 0.000 claims description 47
- 210000004027 cell Anatomy 0.000 claims description 39
- 206010028980 Neoplasm Diseases 0.000 claims description 34
- 239000000427 antigen Substances 0.000 claims description 30
- 102000036639 antigens Human genes 0.000 claims description 30
- 108091007433 antigens Proteins 0.000 claims description 30
- 150000007523 nucleic acids Chemical class 0.000 claims description 30
- 108020004707 nucleic acids Proteins 0.000 claims description 28
- 102000039446 nucleic acids Human genes 0.000 claims description 28
- 230000009826 neoplastic cell growth Effects 0.000 claims description 19
- 208000034578 Multiple myelomas Diseases 0.000 claims description 16
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 16
- 230000000139 costimulatory effect Effects 0.000 claims description 15
- 230000011664 signaling Effects 0.000 claims description 15
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 14
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 14
- 230000003834 intracellular effect Effects 0.000 claims description 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 8
- 208000017604 Hodgkin disease Diseases 0.000 claims description 8
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 8
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 8
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 8
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 8
- 208000005017 glioblastoma Diseases 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 6
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 6
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 5
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 4
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 4
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 3
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 3
- 230000004083 survival effect Effects 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 102100036008 CD48 antigen Human genes 0.000 claims description 2
- 102100025221 CD70 antigen Human genes 0.000 claims description 2
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 2
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 claims description 2
- 108090000177 Interleukin-11 Proteins 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 108090000172 Interleukin-15 Proteins 0.000 claims description 2
- 108050003558 Interleukin-17 Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 108010002386 Interleukin-3 Proteins 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 108010002586 Interleukin-7 Proteins 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 101150030213 Lag3 gene Proteins 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 108010042215 OX40 Ligand Proteins 0.000 claims description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 2
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims description 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 2
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 108010074108 interleukin-21 Proteins 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 210000003738 lymphoid progenitor cell Anatomy 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000003289 regulatory T cell Anatomy 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 46
- 230000008859 change Effects 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 7
- 208000035269 cancer or benign tumor Diseases 0.000 claims 4
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000000034 method Methods 0.000 description 17
- 230000019491 signal transduction Effects 0.000 description 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462088309P | 2014-12-05 | 2014-12-05 | |
| US62/088,309 | 2014-12-05 | ||
| PCT/US2015/064112 WO2016090320A1 (en) | 2014-12-05 | 2015-12-04 | Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020075434A Division JP2020114254A (ja) | 2014-12-05 | 2020-04-21 | Ｂ細胞成熟抗原を標的化するキメラ抗原受容体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537925A JP2017537925A (ja) | 2017-12-21 |
| JP2017537925A5 true JP2017537925A5 (enExample) | 2019-01-17 |
| JP6997620B2 JP6997620B2 (ja) | 2022-02-04 |
Family
ID=56092569
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529746A Active JP6997620B2 (ja) | 2014-12-05 | 2015-12-04 | Ｂ細胞成熟抗原を標的化するキメラ抗原受容体およびその使用 |
| JP2020075434A Withdrawn JP2020114254A (ja) | 2014-12-05 | 2020-04-21 | Ｂ細胞成熟抗原を標的化するキメラ抗原受容体およびその使用 |
| JP2022077378A Pending JP2022105192A (ja) | 2014-12-05 | 2022-05-10 | Ｂ細胞成熟抗原を標的化するキメラ抗原受容体およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020075434A Withdrawn JP2020114254A (ja) | 2014-12-05 | 2020-04-21 | Ｂ細胞成熟抗原を標的化するキメラ抗原受容体およびその使用 |
| JP2022077378A Pending JP2022105192A (ja) | 2014-12-05 | 2022-05-10 | Ｂ細胞成熟抗原を標的化するキメラ抗原受容体およびその使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US10918665B2 (enExample) |
| EP (2) | EP4310097A3 (enExample) |
| JP (3) | JP6997620B2 (enExample) |
| KR (2) | KR102698738B1 (enExample) |
| CN (3) | CN113603795A (enExample) |
| AU (2) | AU2015357526B2 (enExample) |
| CA (1) | CA2969870A1 (enExample) |
| DK (1) | DK3227432T3 (enExample) |
| ES (1) | ES2966099T3 (enExample) |
| FI (1) | FI3227432T3 (enExample) |
| IL (2) | IL252617B (enExample) |
| MX (2) | MX2017007244A (enExample) |
| MY (1) | MY191537A (enExample) |
| NZ (1) | NZ732563A (enExample) |
| PH (1) | PH12017501040B1 (enExample) |
| PL (1) | PL3227432T3 (enExample) |
| PT (1) | PT3227432T (enExample) |
| RU (1) | RU2761632C2 (enExample) |
| SA (1) | SA517381666B1 (enExample) |
| SG (2) | SG10201900931XA (enExample) |
| WO (1) | WO2016090320A1 (enExample) |
Families Citing this family (156)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012088446A1 (en) | 2010-12-22 | 2012-06-28 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| EP4148118A1 (en) | 2012-08-24 | 2023-03-15 | Yale University | System, device and method for high-throughput multi-plexed detection |
| WO2014124280A1 (en) | 2013-02-08 | 2014-08-14 | Institute For Myeloma & Bone Cancer Research | Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma |
| EP3134102B1 (en) | 2014-04-24 | 2019-07-03 | The Board of Trustees of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
| KR102612313B1 (ko) | 2014-07-21 | 2023-12-12 | 노파르티스 아게 | 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료 |
| CN112782140A (zh) | 2014-12-03 | 2021-05-11 | 伊索普莱西斯公司 | 细胞分泌特征的分析和筛选 |
| CN109072199B (zh) * | 2014-12-05 | 2022-10-28 | 纪念斯隆-凯特琳癌症中心 | 靶向Fc受体样5的嵌合抗原受体及其用途 |
| SMT202100221T1 (it) | 2014-12-05 | 2021-07-12 | Memorial Sloan Kettering Cancer Center | Anticorpi bersaglianti l'antigene di maturazione delle cellule e metodi d'uso |
| CN113603795A (zh) | 2014-12-05 | 2021-11-05 | 纪念斯隆-凯特琳癌症中心 | 靶向b-细胞成熟抗原的嵌合抗原受体及其用途 |
| US11353448B2 (en) | 2015-02-13 | 2022-06-07 | California Institute Of Technology | Methods and compositions for quantifying metabolites and proteins from single cells |
| KR102528825B1 (ko) | 2015-04-13 | 2023-05-08 | 화이자 인코포레이티드 | B-세포 성숙 항원을 표적화하는 키메라 항원 수용체 |
| JP2018515123A (ja) | 2015-05-18 | 2018-06-14 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| DK3402515T3 (da) | 2016-01-12 | 2021-11-15 | Oncotracker Inc | Forbedrede fremgangsmåder til monitorering af et individs immunstatus |
| SG10201912515XA (en) | 2016-04-01 | 2020-02-27 | Kite Pharma Inc | Bcma binding molecules and methods of use thereof |
| EP3494138A1 (en) | 2016-08-02 | 2019-06-12 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CN109964126B (zh) | 2016-09-12 | 2022-12-27 | 伊索普莱克西斯公司 | 用于细胞治疗法和其他免疫治疗法的多重分析的系统和方法 |
| IL292551B2 (en) | 2016-10-07 | 2023-10-01 | Tcr2 Therapeutics Inc | Preparations and methods for reprogramming T-cell receptors using fusion proteins |
| US11493508B2 (en) | 2016-11-11 | 2022-11-08 | IsoPlexis Corporation | Compositions and methods for the simultaneous genomic, transcriptomic and proteomic analysis of single cells |
| CN110226084A (zh) | 2016-11-22 | 2019-09-10 | 伊索普莱克西斯公司 | 用于细胞捕获的系统、装置和方法，以及其制造方法 |
| AU2017363311A1 (en) | 2016-11-22 | 2019-06-13 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| CN110121505B (zh) | 2016-12-28 | 2023-08-01 | 株式会社绿十字细胞治疗 | 嵌合抗原受体和表达其的自然杀伤细胞 |
| US20190375815A1 (en) | 2017-01-31 | 2019-12-12 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
| CA3052779A1 (en) | 2017-02-17 | 2018-08-23 | Fred Hutchinson Cancer Research Center | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| CA3059753A1 (en) | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Chimeric antibody/t-cell receptor constructs and uses thereof |
| WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| KR20240139092A (ko) | 2017-05-01 | 2024-09-20 | 주노 쎄러퓨티크스 인코퍼레이티드 | 세포 요법 및 면역조절 화합물의 조합 |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| AU2018367896B2 (en) | 2017-05-12 | 2023-06-01 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| EP3639028B1 (en) | 2017-06-13 | 2025-10-15 | Onco Tracker, Inc. | Diagnostic, prognostic, and monitoring methods for breast cancer |
| US11542312B2 (en) | 2017-06-19 | 2023-01-03 | Medicenna Therapeutics, Inc. | IL-2 superagonists in combination with anti-PD-1 antibodies |
| BR112020001601A2 (pt) | 2017-08-09 | 2020-08-11 | Juno Therapeutics Inc | métodos e composições para preparar células geneticamente manipuladas |
| CA3070579A1 (en) | 2017-08-09 | 2019-02-14 | Juno Therapeutics, Inc. | Methods for producing genetically engineered cell compositions and related compositions |
| EP3679370A1 (en) | 2017-09-07 | 2020-07-15 | Juno Therapeutics, Inc. | Methods of identifying cellular attributes related to outcomes associated with cell therapy |
| BR112020005028A2 (pt) | 2017-09-14 | 2020-09-15 | Glaxosmithkline Intellectual Property Development Limited | tratamento em combinação para câncer |
| JP2020533383A (ja) | 2017-09-14 | 2020-11-19 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 癌の組合せ治療 |
| BR112020005079A2 (pt) | 2017-09-14 | 2020-09-15 | Glaxosmithkline Intellectual Property Development Limited | tratamento de combinação para câncer |
| CN107827989A (zh) * | 2017-10-18 | 2018-03-23 | 银丰生物工程集团有限公司 | 靶向骨髓瘤bcma抗原的转基因t细胞及其制备方法与应用 |
| SG11202003415XA (en) | 2017-10-18 | 2020-05-28 | Novartis Ag | Compositions and methods for selective protein degradation |
| PL3704230T3 (pl) | 2017-11-01 | 2025-02-24 | Juno Therapeutics, Inc. | Proces wytwarzania kompozycji terapeutycznych z komórek zmodyfikowanych genetycznie |
| WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| US11564946B2 (en) | 2017-11-01 | 2023-01-31 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| AU2018358067A1 (en) | 2017-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for B-cell maturation antigen |
| US11066475B2 (en) * | 2017-11-01 | 2021-07-20 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides |
| US11851679B2 (en) | 2017-11-01 | 2023-12-26 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
| EP3704229B1 (en) | 2017-11-01 | 2023-12-20 | Juno Therapeutics, Inc. | Process for producing a t cell composition |
| CN107557342A (zh) * | 2017-11-02 | 2018-01-09 | 广东万海细胞生物科技有限公司 | 一种CAR‑Treg 细胞的制备方法及其应用 |
| CN111886012A (zh) | 2017-11-06 | 2020-11-03 | 朱诺治疗学股份有限公司 | 细胞疗法与γ分泌酶抑制剂的组合 |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| JP2021502829A (ja) * | 2017-11-14 | 2021-02-04 | メモリアル スローン ケタリング キャンサー センター | Ｉｌ−３６を分泌する免疫応答性細胞およびその使用 |
| EP3712178A4 (en) | 2017-11-14 | 2021-08-11 | Green Cross Lab Cell Corporation | ANTI-HER2 ANTIBODIES OR ANTIGIBODY FRAGMENT THEREOF AND CHIMERAIR ANTIGEN RECEPTOR WITH IT |
| RU2020119365A (ru) | 2017-11-15 | 2021-12-13 | Новартис Аг | Химерный антигенный рецептор, нацеливающийся на всма, химерный антигенный рецептор, нацеливающийся на cd19, и средства комбинированной терапии |
| MX2020005651A (es) | 2017-11-30 | 2020-10-28 | Novartis Ag | Receptor de antigeno quimerico dirigido a bcma y usos del mismo. |
| KR20200116081A (ko) | 2017-12-01 | 2020-10-08 | 주노 쎄러퓨티크스 인코퍼레이티드 | 유전자 조작된 세포의 투약 및 조절 방법 |
| MX2020005908A (es) | 2017-12-08 | 2020-10-07 | Juno Therapeutics Inc | Proceso para producir una composicion de celulas t modificadas. |
| JP7433230B2 (ja) | 2017-12-08 | 2024-02-19 | ジュノー セラピューティクス インコーポレイテッド | 細胞を培養するための無血清培地配合物およびその使用の方法 |
| KR20250141843A (ko) | 2017-12-08 | 2025-09-29 | 주노 쎄러퓨티크스 인코퍼레이티드 | 세포 요법을 위한 표현형 마커 및 관련 방법 |
| EP3737408A1 (en) | 2018-01-08 | 2020-11-18 | Novartis AG | Immune-enhancing rnas for combination with chimeric antigen receptor therapy |
| EP3746116A1 (en) | 2018-01-31 | 2020-12-09 | Novartis AG | Combination therapy using a chimeric antigen receptor |
| PL3674328T3 (pl) * | 2018-02-01 | 2024-09-16 | Nanjing IASO Biotechnology Co., Ltd. | Chimeryczny receptor antygenu (car) wiążący się z bcma i jego zastosowania |
| EP3752203A1 (en) | 2018-02-13 | 2020-12-23 | Novartis AG | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| SG11202010262TA (en) * | 2018-04-19 | 2020-11-27 | Baylor College Medicine | Reprogramming cd4 t cells into cytotoxic cd8 cells by forced expression of cd8ab and class 1 restricted t cell receptors |
| MX2020012028A (es) | 2018-05-11 | 2021-03-29 | Crispr Therapeutics Ag | Metodos y composiciones para tratar el cancer. |
| MX2020012561A (es) | 2018-05-24 | 2021-01-29 | Ayala Pharmaceuticals Inc | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiazepinona e inmunoterapeuticos y metodos de uso de las mismas. |
| CA3100724A1 (en) * | 2018-06-13 | 2019-12-19 | Novartis Ag | B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| SMT202500371T1 (it) | 2018-07-19 | 2025-11-10 | Regeneron Pharma | Recettori chimerici dell’antigene con specificità per bcma e loro usi |
| KR20210059715A (ko) | 2018-08-09 | 2021-05-25 | 주노 쎄러퓨티크스 인코퍼레이티드 | 통합된 핵산 평가 방법 |
| EP3833742A2 (en) | 2018-08-09 | 2021-06-16 | Juno Therapeutics, Inc. | Processes for generating engineered cells and compositions thereof |
| CN109134665B (zh) * | 2018-08-24 | 2021-06-11 | 上海先博生物科技有限公司 | 一种基于单域抗体的bcma嵌合抗原受体及应用 |
| EP3844265A2 (en) | 2018-08-31 | 2021-07-07 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
| TW202538050A (zh) | 2018-08-31 | 2025-10-01 | 瑞士商諾華公司 | 製備表現嵌合抗原受體的細胞之方法 |
| US20220017926A1 (en) * | 2018-09-21 | 2022-01-20 | Cafa Therapeutics Limited | Method for gene editing of cell on the basis of crispr/cas system |
| DK3833682T3 (da) | 2018-10-01 | 2022-10-03 | Caribou Biosciences Inc | Selvmordsmolekyle sammensætninger og fremgangsmåder |
| WO2020073215A1 (zh) * | 2018-10-10 | 2020-04-16 | 深圳华大生命科学研究院 | 抗BCMA单链抗体scFv及其制备方法和应用 |
| EP3867279A4 (en) * | 2018-10-19 | 2022-07-13 | Memorial Sloan Kettering Cancer Center | AN AGAINST SIALYL-LEWIS A CHIMERIC ANTIGEN RECEPTOR AND ITS USES |
| JP2022509454A (ja) | 2018-10-31 | 2022-01-20 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 癌の処置法 |
| CN113227358A (zh) | 2018-10-31 | 2021-08-06 | 朱诺治疗学有限公司 | 选择并刺激细胞的方法及用于所述方法的设备 |
| BR112021008289A2 (pt) * | 2018-11-01 | 2021-10-26 | Juno Therapeutics, Inc. | Métodos para tratamento utilizando receptores de antígeno quimérico específico para antígeno de maturação de célula b |
| TW202021981A (zh) | 2018-11-01 | 2020-06-16 | 美商奇諾治療有限公司 | G蛋白偶合受體c類第5群成員d（gprc5d）特異性嵌合抗原受體 |
| BR112021008930A2 (pt) | 2018-11-08 | 2021-11-03 | Juno Therapeutics Inc | Métodos e combinações para o tratamento e modulação de célula t |
| CN113710256A (zh) | 2018-11-30 | 2021-11-26 | 朱诺治疗学股份有限公司 | 使用过继细胞疗法的治疗方法 |
| CA3126087A1 (en) | 2019-02-25 | 2020-09-03 | Novartis Ag | Mesoporous silica particles compositions for viral delivery |
| WO2020180882A1 (en) | 2019-03-05 | 2020-09-10 | Nkarta, Inc. | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| WO2020191316A1 (en) | 2019-03-21 | 2020-09-24 | Novartis Ag | Car-t cell therapies with enhanced efficacy |
| CN113677664B (zh) | 2019-04-12 | 2025-04-04 | C4医药公司 | Ikaros和aiolos的三环降解物 |
| WO2020210678A1 (en) | 2019-04-12 | 2020-10-15 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| US20220251152A1 (en) | 2019-04-24 | 2022-08-11 | Novartis Ag | Compositions and methods for selective protein degradation |
| EP3962535A1 (en) | 2019-04-30 | 2022-03-09 | CRISPR Therapeutics AG | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| SG11202112006WA (en) * | 2019-04-30 | 2021-11-29 | Memorial Sloan Kettering Cancer Center | Combination therapies |
| CA3136742A1 (en) | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods |
| SG11202111360YA (en) | 2019-05-01 | 2021-11-29 | Juno Therapeutics Inc | Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods |
| CN114269371A (zh) | 2019-06-12 | 2022-04-01 | 朱诺治疗学股份有限公司 | 细胞介导的细胞毒性疗法与促存活bcl2家族蛋白的抑制剂的组合疗法 |
| CN114502593A (zh) | 2019-08-06 | 2022-05-13 | 葛兰素史密斯克莱知识产权发展有限公司 | 生物药物组合物和相关方法 |
| KR20220066892A (ko) | 2019-08-22 | 2022-05-24 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ｔ 세포 요법 및 제스트 동족체 2의 인핸서 (ｅｚｈ2) 억제제의 병용 요법 및 관련 방법 |
| BR112022008023A2 (pt) | 2019-10-30 | 2022-07-12 | Juno Therapeutics Gmbh | Dispositivos de seleção e/ou estimulação de células e métodos de uso |
| IL293215A (en) | 2019-11-26 | 2022-07-01 | Novartis Ag | Chimeric antigen receptors that bind bcma and cd19 and their uses |
| JP2023504740A (ja) | 2019-12-06 | 2023-02-06 | ジュノー セラピューティクス インコーポレイテッド | Ｂｃｍａ標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法 |
| US20230192869A1 (en) | 2019-12-06 | 2023-06-22 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods |
| US20230090117A1 (en) | 2020-01-28 | 2023-03-23 | Juno Therapeutics, Inc. | Methods for t cell transduction |
| IL295381A (en) | 2020-02-12 | 2022-10-01 | Juno Therapeutics Inc | bcma-directed chimeric t-cell antigen receptor compounds and methods and uses thereof |
| TW202146441A (zh) | 2020-02-27 | 2021-12-16 | 瑞士商諾華公司 | 製備表現嵌合抗原受體的細胞之方法 |
| CA3173737A1 (en) | 2020-02-27 | 2021-09-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| WO2021207689A2 (en) | 2020-04-10 | 2021-10-14 | Juno Therapeutics, Inc. | Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen |
| BR112022021788A2 (pt) | 2020-04-28 | 2023-01-17 | Juno Therapeutics Inc | Combinação de terapia com células t direcionada para bcma e um composto imunomodulador |
| JP7727662B2 (ja) | 2020-05-13 | 2025-08-21 | ジュノー セラピューティクス インコーポレイテッド | 臨床応答に関連する特徴量の特定方法およびその使用 |
| US20230332104A1 (en) | 2020-06-11 | 2023-10-19 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| JP2023531531A (ja) | 2020-06-26 | 2023-07-24 | ジュノ セラピューティクス ゲーエムベーハー | 組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法 |
| EP4192868A1 (en) | 2020-08-05 | 2023-06-14 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods |
| US20230302155A1 (en) | 2020-08-21 | 2023-09-28 | Novartis Ag | Compositions and methods for in vivo generation of car expressing cells |
| CN116802203A (zh) | 2020-11-04 | 2023-09-22 | 朱诺治疗学股份有限公司 | 从经修饰的恒定cd3免疫球蛋白超家族链基因座表达嵌合受体的细胞、相关多核苷酸和方法 |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| WO2022187406A1 (en) | 2021-03-03 | 2022-09-09 | Juno Therapeutics, Inc. | Combination of a t cell therapy and a dgk inhibitor |
| AU2022244229A1 (en) | 2021-03-22 | 2023-09-14 | Juno Therapeutics, Inc. | Method to assess potency of viral vector particles |
| WO2022204070A1 (en) | 2021-03-22 | 2022-09-29 | Juno Therapeutics, Inc. | Methods of determining potency of a therapeutic cell composition |
| EP4322991A1 (en) | 2021-04-16 | 2024-02-21 | Celgene Corporation | T cell therapy in patients who have had prior stem cell transplant |
| JP2024514163A (ja) | 2021-04-16 | 2024-03-28 | セルジーン コーポレーション | Ｂｃｍａ指向性ｔ細胞療法を用いた併用療法 |
| US20240384293A1 (en) | 2021-04-27 | 2024-11-21 | Novartis Ag | Viral vector production system |
| CN117916256A (zh) | 2021-05-06 | 2024-04-19 | 朱诺治疗学有限公司 | 用于刺激和转导t细胞的方法 |
| CN117396513A (zh) | 2021-05-28 | 2024-01-12 | 葛兰素史密斯克莱知识产权发展有限公司 | 治疗癌症的联合疗法 |
| CA3224478A1 (en) * | 2021-07-12 | 2023-01-19 | Kanya Lakshmi RAJANGAM | Bcma-directed cellular immunotherapy compositions and methods |
| KR20240040786A (ko) | 2021-08-03 | 2024-03-28 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 생물제약 조성물 및 안정한 동위원소 표지 펩티드 맵핑 방법 |
| US20250000973A1 (en) | 2021-08-20 | 2025-01-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| CN118159294A (zh) | 2021-10-05 | 2024-06-07 | 葛兰素史密斯克莱知识产权发展有限公司 | 用于治疗癌症的联合疗法 |
| JP2024540320A (ja) | 2021-11-03 | 2024-10-31 | セルジーン コーポレーション | 骨髄腫を処置する際に使用するための、ｂ細胞成熟抗原に特異的なキメラ抗原受容体 |
| EP4469484A1 (en) | 2022-01-25 | 2024-12-04 | GlaxoSmithKline Intellectual Property Development Ltd | Combination therapy for cancer |
| CN119013393A (zh) | 2022-01-28 | 2024-11-22 | 朱诺治疗学股份有限公司 | 制造细胞组合物的方法 |
| WO2023213969A1 (en) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
| KR20250008774A (ko) | 2022-05-11 | 2025-01-15 | 셀진 코포레이션 | T 세포 요법 및 그의 생산과 관련된 방법 및 용도 |
| WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| EP4525899A1 (en) | 2022-05-17 | 2025-03-26 | Umoja Biopharma, Inc. | Manufacturing viral particles |
| EP4532695A1 (en) | 2022-05-25 | 2025-04-09 | Celgene Corporation | Methods of manufacturing t cell therapies |
| WO2023230548A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Method for predicting response to a t cell therapy |
| CA3259061A1 (en) | 2022-06-10 | 2023-12-14 | Umoja Biopharma, Inc. | MODIFIED STEM CELLS AND THEIR USES |
| JP2025525937A (ja) | 2022-08-05 | 2025-08-07 | ジュノー セラピューティクス インコーポレイテッド | Ｇｐｒｃ５ｄおよびｂｃｍａに特異的なキメラ抗原受容体 |
| CN120152717A (zh) | 2022-09-08 | 2025-06-13 | 朱诺治疗学股份有限公司 | T细胞疗法和连续或间歇dgk抑制剂给药的组合 |
| CN120112650A (zh) | 2022-10-26 | 2025-06-06 | 诺华股份有限公司 | 慢病毒配制品 |
| WO2024097905A1 (en) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
| TW202434735A (zh) | 2022-11-04 | 2024-09-01 | 美商烏莫賈生物製藥股份有限公司 | 展示黏著分子融合的顆粒 |
| WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
| WO2024119126A1 (en) * | 2022-12-02 | 2024-06-06 | Artiva Biotherapeutics, Inc. | Anti-bcma antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| EP4630454A1 (en) | 2022-12-05 | 2025-10-15 | GlaxoSmithKline Intellectual Property Development Ltd | Methods of treatment using b-cell maturation antigen antagonists |
| WO2024124132A1 (en) | 2022-12-09 | 2024-06-13 | Juno Therapeutics, Inc. | Machine learning methods for predicting cell phenotype using holographic imaging |
| AU2024214593A1 (en) | 2023-02-03 | 2025-08-07 | C3S2 Gmbh | Methods for non-viral manufacturing of engineered immune cells |
| WO2024168192A1 (en) | 2023-02-10 | 2024-08-15 | Celgene Corporation | Assessment of bcma in biological samples |
| KR20250169631A (ko) | 2023-04-18 | 2025-12-03 | 주노 쎄러퓨티크스 인코퍼레이티드 | 치료 세포 조성물의 효력을 평가하기 위한 세포독성 검정 |
| WO2024243365A2 (en) | 2023-05-23 | 2024-11-28 | Juno Therapeutics, Inc. | Activation markers of t cells and method for assessing t cell activation |
| WO2025129084A1 (en) | 2023-12-13 | 2025-06-19 | Umoja Biopharma, Inc. | Engineered induced stem cell derived myeloid cells and methods of differentiating and using same |
| WO2025147545A1 (en) | 2024-01-03 | 2025-07-10 | Juno Therapeutics, Inc. | Lipid nanoparticles for delivery of nucleic acids and related methods and uses |
| WO2025171383A2 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens and related methods and uses |
| WO2025171388A1 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens with modified domains and related methods and uses |
| WO2025231174A1 (en) | 2024-04-30 | 2025-11-06 | Umoja Biopharma, Inc. | Manufacturing viral particles |
| WO2025235604A1 (en) | 2024-05-08 | 2025-11-13 | Umoja Biopharma, Inc. | Fusion protein for use as immune cell engager |
| WO2026006767A1 (en) | 2024-06-28 | 2026-01-02 | Dispatch Biotherapeutics, Inc. | Tethered il-9/il-9r and related engineered cells and methods |
| WO2026020055A2 (en) | 2024-07-18 | 2026-01-22 | Juno Therapeutics, Inc. | Methods for assessing exosomes in a cell composition and related uses |
| WO2026025092A1 (en) | 2024-07-26 | 2026-01-29 | Juno Therapeutics, Inc. | Synthetic promoters for t cell expression |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| NZ517782A (en) | 1999-08-17 | 2004-01-30 | Biogen Inc | A beta-cell activating factor receptor belonging to the TNF family is used as a pharmaceutical agent and in the treatment of disease |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
| PT2275449T (pt) | 2000-06-16 | 2016-12-27 | Human Genome Sciences Inc | Anticorpos que se ligam imunoespecificamente a blys |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| JP5586952B2 (ja) | 2006-06-06 | 2014-09-10 | クルセル ホランド ベー ヴェー | 腸球菌に対する殺活性を有するヒトの結合分子及びその使用方法 |
| SI2132230T1 (sl) * | 2007-03-22 | 2014-07-31 | Genentech, Inc. | Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE |
| EP2537416B1 (en) | 2007-03-30 | 2014-11-12 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| DK2356270T3 (da) | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
| HUE029619T4 (en) | 2009-03-10 | 2017-07-28 | Biogen Ma Inc | Anti-bcma antibodies |
| SI2496698T1 (sl) | 2009-11-03 | 2019-07-31 | City Of Hope | Skrajšan epiderimalni receptor faktorja rasti (EGFRt) za selekcijo transduciranih T celic |
| PL3459564T3 (pl) | 2010-01-06 | 2022-04-19 | Takeda Pharmaceutical Company Limited | Białka wiążące kalikreinę osocza |
| JP2011178691A (ja) | 2010-02-26 | 2011-09-15 | Takuya Ueda | カテニン結合プローブとその用途 |
| WO2012066058A1 (en) * | 2010-11-16 | 2012-05-24 | Boehringer Ingelheim International Gmbh | Agents and methods for treating diseases that correlate with bcma expression |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US20130101599A1 (en) | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| HK1203393A1 (en) * | 2012-04-11 | 2015-10-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| EP2674439B1 (en) | 2012-06-13 | 2017-02-01 | Rottapharm Biotech S.r.l. | Anti-TrkA antibodies, derivatives and uses thereof |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| US9243058B2 (en) | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
| WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| HRP20201419T1 (hr) | 2013-02-26 | 2020-12-11 | Memorial Sloan Kettering Cancer Center | Pripravci i postupci za imunoterapiju |
| EP3004337B1 (en) | 2013-05-29 | 2017-08-02 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| ES2939760T3 (es) | 2014-03-15 | 2023-04-26 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico para antígenos |
| CA2945620C (en) | 2014-04-14 | 2022-12-06 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| KR102612313B1 (ko) | 2014-07-21 | 2023-12-12 | 노파르티스 아게 | 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료 |
| US20170226216A1 (en) | 2014-07-24 | 2017-08-10 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
| SMT202100221T1 (it) | 2014-12-05 | 2021-07-12 | Memorial Sloan Kettering Cancer Center | Anticorpi bersaglianti l'antigene di maturazione delle cellule e metodi d'uso |
| CN113603795A (zh) | 2014-12-05 | 2021-11-05 | 纪念斯隆-凯特琳癌症中心 | 靶向b-细胞成熟抗原的嵌合抗原受体及其用途 |
| EP3640262A1 (en) | 2014-12-12 | 2020-04-22 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors for use in the treatment of a hematological malignancy |
| US11066475B2 (en) | 2017-11-01 | 2021-07-20 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides |
-
2015
- 2015-12-04 CN CN202111021056.1A patent/CN113603795A/zh active Pending
- 2015-12-04 SG SG10201900931XA patent/SG10201900931XA/en unknown
- 2015-12-04 PL PL15864826.1T patent/PL3227432T3/pl unknown
- 2015-12-04 EP EP23198934.4A patent/EP4310097A3/en active Pending
- 2015-12-04 KR KR1020177018390A patent/KR102698738B1/ko active Active
- 2015-12-04 MX MX2017007244A patent/MX2017007244A/es unknown
- 2015-12-04 AU AU2015357526A patent/AU2015357526B2/en not_active Ceased
- 2015-12-04 KR KR1020247027969A patent/KR20240130831A/ko not_active Withdrawn
- 2015-12-04 DK DK15864826.1T patent/DK3227432T3/da active
- 2015-12-04 PT PT158648261T patent/PT3227432T/pt unknown
- 2015-12-04 IL IL252617A patent/IL252617B/en unknown
- 2015-12-04 ES ES15864826T patent/ES2966099T3/es active Active
- 2015-12-04 CN CN202111021055.7A patent/CN113698497A/zh active Pending
- 2015-12-04 SG SG11201704549UA patent/SG11201704549UA/en unknown
- 2015-12-04 JP JP2017529746A patent/JP6997620B2/ja active Active
- 2015-12-04 EP EP15864826.1A patent/EP3227432B1/en active Active
- 2015-12-04 RU RU2017123548A patent/RU2761632C2/ru active
- 2015-12-04 IL IL295298A patent/IL295298A/en unknown
- 2015-12-04 MY MYPI2017000854A patent/MY191537A/en unknown
- 2015-12-04 FI FIEP15864826.1T patent/FI3227432T3/fi active
- 2015-12-04 CN CN201580075540.9A patent/CN107208047B/zh active Active
- 2015-12-04 NZ NZ732563A patent/NZ732563A/en not_active IP Right Cessation
- 2015-12-04 WO PCT/US2015/064112 patent/WO2016090320A1/en not_active Ceased
- 2015-12-04 PH PH1/2017/501040A patent/PH12017501040B1/en unknown
- 2015-12-04 CA CA2969870A patent/CA2969870A1/en active Pending
-
2017
- 2017-06-05 MX MX2022001293A patent/MX2022001293A/es unknown
- 2017-06-05 US US15/613,638 patent/US10918665B2/en active Active
- 2017-06-05 SA SA517381666A patent/SA517381666B1/ar unknown
-
2020
- 2020-04-09 US US16/844,610 patent/US11000549B2/en active Active
- 2020-04-09 US US16/844,759 patent/US10821135B2/en active Active
- 2020-04-21 JP JP2020075434A patent/JP2020114254A/ja not_active Withdrawn
-
2021
- 2021-04-12 US US17/228,213 patent/US20210346432A1/en not_active Abandoned
-
2022
- 2022-05-10 JP JP2022077378A patent/JP2022105192A/ja active Pending
- 2022-06-15 AU AU2022204181A patent/AU2022204181A1/en not_active Abandoned
-
2024
- 2024-06-20 US US18/749,513 patent/US20240335475A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537925A5 (enExample) | ||
| JP2017537629A5 (enExample) | ||
| RU2017123548A (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток, и их применение | |
| JP7419434B2 (ja) | 新規のポリペプチド | |
| JP2018504094A5 (enExample) | ||
| KR102483755B1 (ko) | 키메라 폴리펩티드 및 그의 용도 | |
| JP7148539B2 (ja) | 免疫抱合体 | |
| HRP20211978T1 (hr) | Kimerični antigenski receptori koji ciljaju receptor spojen na g-protein i njihove uporabe | |
| JP2025060983A (ja) | 免疫細胞機能をモジュレートするための変異体インターロイキン－２ポリペプチドと抗原結合分子の融合体 | |
| CN107428830B (zh) | 单体fc结构域 | |
| US12421292B2 (en) | Anti-DLL3 chimeric antigen receptors and uses thereof | |
| US11713356B2 (en) | Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer | |
| JP2019527537A5 (enExample) | ||
| JP2023010753A (ja) | プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体 | |
| RS63663B1 (sr) | Imunokonjugati anti-pd-1 antitela sa mutantom il-2 ili sa il-15 | |
| CN110709421A (zh) | 针对ox40和ctla-4的双特异性抗体 | |
| JP2020514363A5 (enExample) | ||
| CN114269785A (zh) | 免疫刺激性多聚体结合分子 | |
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| IL268901B1 (en) | Human immunoglobulin M constant regions adapted for modulation of complement-dependent cytolysis factor activity | |
| JP2017519494A (ja) | Ｏｘ４０ｌ融合タンパク質およびその使用 | |
| JP2016520074A5 (enExample) | ||
| CN111727057A (zh) | 与lag3和pd1结合的治疗分子 | |
| JP2023521238A (ja) | 免疫複合体 | |
| JP7674278B2 (ja) | 抗ニューヨーク食道扁平上皮がん１（ｎｙ－ｅｓｏ－１）抗原結合タンパク質およびその使用方法 |